Silvy da Rocha Dias

Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice

Nathalie Dhomen, Jorge S. Reis‐Filho, Silvy da Rocha Dias et al. · Cancer Cell · 2009 · 578 citations · Full text

Medicine, Molecular Biology, Oncology +12

Activated B-RAF Is an Hsp90 Client Protein That Is Targeted by the Anticancer Drug 17-Allylamino-17-Demethoxygeldanamycin

Silvy da Rocha Dias, Frank Friedlos, Yvonne Light et al. · Cancer Research · 2005 · 247 citations

Medicine, Cancer Biology, Oncology +15

CTLA-4 up-regulation of lymphocyte function-associated antigen 1 adhesion and clustering as an alternate basis for coreceptor function

Helga Schneider, Elke Valk, Silvy da Rocha Dias et al. · Proceedings of the National Academy of Sciences · 2005 · 121 citations · Full text

Life Sciences, Cell Biology, Immunology +17

The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use

Silvy da Rocha Dias, Tomas Salmonson, Barbara van Zwieten‐Boot et al. · European Journal of Cancer · 2013 · 54 citations

Pharmacy, Oncology, Pharmacotherapy +13

A regulatory role for cytoplasmic YVKM motif in CTLA-4 inhibition of TCR signaling

Helga Schneider, Silvy da Rocha Dias, Hui Hu et al. · European Journal of Immunology · 2001 · 38 citations · Full text

Life Sciences, Immunology, Molecular Biology +17